The purpose of this research is to determine whether peanut consumption improves indicators of cardiovascular disease (CVD) risk in human subjects following the consumption of study foods.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change in psychosocial stress over time
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of allostatic load following dietary interventions
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of monocyte gene expression
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of cytokine and interferon production in PBMCs
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of cytotoxicity of peripheral natural killer cells
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of interferon-gamma
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of tumor necrosis factors alpha and beta
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of interleukins
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of fibroblast growth factor
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of granulocyte-macrophage colony-stimulating factor
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of thymus and activation-regulated chemokine
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of macrophage inflammatory proteins-1 alpha and beta
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of macrophage-derived chemokine
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of monocyte chemoattractant proteins-1 and -4
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of interferon gamma-induced protein-10
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of eotaxin and eotaxin-3
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of C-reactive protein
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of intercellular adhesion molecule-1
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of placental growth factor
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of serum amyloid A
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of angiopoietin-1 receptor
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of vascular cell adhesion molecule-1
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of vascular endothelial growth factors A, C, and D
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of vascular endothelial growth factor receptor-1
Timeframe: Baseline, 4 weeks, 8 weeks, and 12 weeks
Change from baseline of monocyte phenotype
Timeframe: Baseline, 4 weeks, 8 weeks, 12 weeks
Change from baseline of monocyte functional profile
Timeframe: Baseline, 4 weeks, 8 weeks, 12 weeks
Change from baseline of natural killer cell phenotype
Timeframe: Baseline, 4 weeks, 8 weeks, 12 weeks
Change from baseline of natural killer cell functional profile
Timeframe: Baseline, 4 weeks, 8 weeks, 12 weeks